BiotechTube

IFX-1 + Placebo-IFX-1 + Glucocorticoid (GC) + Placebo-Glucocorticoid (Placebo-GC)

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Granulomatosis With Polyangiitis (GPA)

Conditions

Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)

Trial Timeline

Apr 3, 2019 → Jun 8, 2021

NCT ID
NCT03895801

About IFX-1 + Placebo-IFX-1 + Glucocorticoid (GC) + Placebo-Glucocorticoid (Placebo-GC)

IFX-1 + Placebo-IFX-1 + Glucocorticoid (GC) + Placebo-Glucocorticoid (Placebo-GC) is a phase 2 stage product being developed by InflaRx for Granulomatosis With Polyangiitis (GPA). The current trial status is completed. This product is registered under clinical trial identifier NCT03895801. Target conditions include Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA).

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03895801Phase 2Completed

Competing Products

9 competing products in Granulomatosis With Polyangiitis (GPA)

See all competitors
ProductCompanyStageHype Score
NS-229 + PlaceboNippon ShinyakuPhase 2
52
BenralizumabAstraZenecaPhase 3
77
Tezepelumab + PlaceboAstraZenecaPhase 2
52
RituximabRocheApproved
85
RituximabRochePhase 2
52
Methylprednisolone + Prednisone + RituximabRocheApproved
85
Avacopan + PlaceboAmgenPhase 2/3
64
Abatacept + placeboBristol Myers SquibbPhase 3
76
IFX-1 low dose + IFX-1 high dose + PlaceboInflaRxPhase 2
44

Other Products from InflaRx

vilobelimab + PlaceboPhase 3
69
IFX-1 + BSC + BSC + IFX-1 + SOC + Placebo + SOCPhase 2/3
57
Cohort A: vilobelimab + Cohort A: placebo + Cohort B: paridiprubart + Cohort B: placebo + Cohort C: bevacizumab + Cohort C: placeboPhase 2
44
Cohort C: bevacizumab + Cohort C: placeboPhase 2
44
IFX-1 + PlaceboPhase 2
44